Fierce Pharma March 27, 2024
As geopolitical tensions threaten to disrupt pharmaceutical supply chains, AstraZeneca is making plans to manufacture drugs for the U.S. and China markets independently from one another.
“We have a very large supply chain, and we are organizing ourselves so that we can actually supply the United States and Europe independently,” AstraZeneca CEO said in an interview with Bloomberg on the sidelines of the Boao Forum for Asia in China. “And we also are building our presence here in China, so we can actually supply Chinese patients independently.”
Soriot pointed to AZ’s recently announced $300 million cell therapy facility in Rockville, Maryland, following the company’s $1 billion acquisition of Chinese CAR-T biotech Gracell Biotechnologies.
“The fact that a product is invented...
Today's Sponsors
Today's Sponsor